BCR-ABL

Launch Interactive

Topic

Resource Type

Level

Potential to Adapt for Middle School High School — General High School — AP/IB College

View in Spanish

Description

This model shows the structure of the protein BCR-ABL, which causes a type of cancer called chronic myeloid leukemia.

Chronic myeloid leukemia (CML) is a cancer of white blood cells. In CML, white blood cells divide uncontrollably due to an overactive tyrosine kinase protein called BCR-ABL, which results from a chromosomal translocation. The model shows the ABL kinase domain of the mutant protein, which includes a binding site for ATP.

The 3D model can be viewed and rotated in the online 3D Viewer. The accompanying downloads provide other ways to display and interact with the model. The “3D Preview” contains an image of the model that can be viewed and rotated within Adobe Acrobat. The “3D Movie Loop” is a short looping animation that shows the model being rotated. The “3D Printing Data” STL file allows the model to be printed on a 3D printer.

Note that the STL file can be viewed with the free MakerWare software from MakerBot, but MakerWare will print only to a MakerBot printer. Please use the software provided with your 3D printer to print the STL file.

Details

Key Terms

cancer, Gleevec, health care, imatinib, medicine, mutation, protein, tyrosine kinase

The resource is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license. No rights are granted to use HHMI’s or BioInteractive’s names or logos independent from this Resource or in any derivative works.

Version History

Date Published 05.23.14

Educator Tips

Hear how educators are using BioInteractive content in their teaching.

Educator standing in front of an image of worksheet.

Play Video Next Slide Next Slide

1-Minute Tips

BCR-ABL Cancer Protein Structure and Function

Mary Wuerth explains how she uses the BCR-ABL Click & Learn to teach the importance of protein structure in understanding how proteins work, and how scientists use that knowledge to design drugs to fight cancer.

View Article

Previous Slide Next Slide